About SpringWorks Therapeutics
SpringWorks Therapeutics is a Healthcare company based in New York (United States) founded in 2017, and was acquired by Merck in April 2025. Small molecule therapeutics are developed for cancer and rare diseases. SpringWorks Therapeutics has raised $229.6 million across 4 funding rounds from investors including Pfizer, Merck and Citadel. Its chief executive, as recorded, is Saqib Islam. Its website springworkstx.com draws about 14 thousand monthly visits. SpringWorks Therapeutics offers products and services including Nirogacestat and Mirdametinib. Its focus areas include Life Sciences, Oncology, Drugs and Bone Cancer. Its legal entity is SpringWorks Therapeutics, Inc. Its competitors include QSAM Biosciences, Vuja De Sciences and ECM Therapeutics; 2 of its 3 listed competitors have raised funding.
Company details
Founded in 2017 and based in New York, United States, small molecule therapeutics are developed by SpringWorks Therapeutics within the biotechnology sector for cancer and rare diseases. Operations focus on advancing candidates such as Nirogacestat, a gamma-secretase inhibitor targeting desmoid tumors, a MEK 12 inhibitor for neurofibromatosis type 1, and senicapoc for hereditary xerocytosis involving dehydrated red blood cells.
Products & Services of SpringWorks Therapeutics
SpringWorks Therapeutics offers a comprehensive portfolio of products and services, including Nirogacestat and Mirdametinib.
Gamma secretase inhibitor for BCMA combinations in multiple myeloma.
Treatment for NF1-PN in pediatric and adult patients.
Apps and channels of SpringWorks Therapeutics
its YouTube channel SpringWorks Therapeutics has 58 subscribers and 12 videos.
Videos from SpringWorks Therapeutics
The most watched videos on SpringWorks Therapeutics's YouTube channel, SpringWorks Therapeutics (58 subscribers). Click a video to play it here.
More on SpringWorks Therapeutics.
Funding Insights of SpringWorks Therapeutics
SpringWorks Therapeutics has successfully raised a total of $229.6M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $225 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $229.6M
- Total Rounds 4
- Last Round Post-IPO — $225M
- First Round $103M
(Sep 2017)
- Investors Count 17
All 4 funding rounds of SpringWorks Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2022 | $225M | Post-IPO | – | – | |
| Apr 2019 | $125M | Series B | – | Perceptive Advisors | |
| Dec 2017 | $1.6M | Series A | – | – | – |
| Sep 2017 | $103M | Series A | – | – |
18 investors in total: 18 institutional.
Investors in SpringWorks Therapeutics
SpringWorks Therapeutics has secured backing from 18 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Merck and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biotech startups are funded by this venture capital firm. | boxercap.com | San Diego, United States | ||
Long-term private equity investments in transformational opportunities are pursued. | invus.com | New York, United States | ||
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
US private equity investments are managed by BVF Partners. | bvflp.com | San Francisco, United States | ||
Venture capital funding is provided by Samsara BioCapital in California. | samsaracap.com | Palo Alto, United States | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Late-stage life sciences investments are managed via VC and PE. | hbmpartners.com | Zug, Switzerland | ||
Investments are focused on pharmaceutical, biotechnology, and medical sectors. | baincapitallifesciences.com | Boston, United States | ||
Impact investing in health, education, and sustainability with a focus on financial and social returns. | baincapitaldoubleimpact.com |
Investor details for SpringWorks Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of SpringWorks Therapeutics
109 people are tracked at SpringWorks Therapeutics (65 in leadership, 6 in board & advisors, 38 in team).
| Name | Role | Group |
|---|---|---|
Saqib Islam | CEO | Leadership |
Francis Perier | Chief Financial Officer | Leadership |
Gregory J. Decker | Vice President Information Technology | Leadership |
Kristin Patterson | Chief Technical Operations Officer | Leadership |
Daniel Pichl | Chief People Officer | Leadership |
Brandy W. | Director Of Commercial Operations - Chief Of Staff- Sales And Marketing Operations | Leadership |
Jerry Dermon | Regional Business Director - West | Leadership |
Jervis Nunez | Sr Director, IT Infrastructure & Operations | Leadership |
Joseph Calarco | Executive Director, Compliance | Leadership |
Heta Patel | Compliance Manager, Business Partner | Leadership |
Issbah K. | Associate Director, Strategic Operations | Leadership |
Kate Procaccini | Director, Marketing Operations | Leadership |
Kristen Turner | Head Of Talent Acquisition | Leadership |
Gioacchino Amari | Associate Talent Attraction And Enablement Director | Leadership |
Cristina Kandesse Wang | Vice President, Controller | Leadership |
Jasna Vattoth | Director, Corporate Accounting | Leadership |
Benjamin Adler | Vice President, Strategy And Business Development | Leadership |
Kristin Kohlmeir | Director, US Marketing | Leadership |
Andrea Zide | Senior Director, Digital And Omnichannel Strategy | Leadership |
Gregory Marthe | Regional Business Director | Leadership |
89 more people are available in the full profile.
Complete people profiles for SpringWorks Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of SpringWorks Therapeutics
5 dated milestones of SpringWorks Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded SpringWorks Therapeutics is founded.
- Funding First funding round of $103.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $225.0M.
- Exit Acquired by Merck.
Competitors of SpringWorks Therapeutics
SpringWorks Therapeutics has 3 listed competitors in our database, 2 of them funded. They include QSAM Biosciences, Vuja De Sciences and ECM Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| qsambio.com | 2004 | Palm Beach, United States | 4 | Developer of nuclear medicines for the treatment of bone cancer treatment & bone marrow ablation | ||
| vujade-life.com | 2017 | Hoboken, United States | $3.94M | Therapies for preventing cancer metastasis and recurrence are developed. | ||
| ecmtherapeutics.com | 2018 | Warrendale, United States | $26.1M | Diagnostic and therapeutic products from extracellular matrix are developed. |
Detailed competitors of SpringWorks Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of SpringWorks Therapeutics
The website of SpringWorks Therapeutics (springworkstx.com) receives about 13.6K visits a month and ranks #1,818,175 among all websites worldwide, #2,480 in Biotechnology and Pharmaceuticals.
- Monthly visits13.6K
▼ 2.8% vs previous month
- Unique visitors7.6K
per month
- Global rank#1,818,175
among all websites
- Category rank#2,480
Health · Biotechnology and Pharmaceuticals
- Bounce rate47%
- Pages per visit1.5
- Average visit10 sec
- DevicesDesktop 31% · Mobile 69%
Websites whose visitors overlap most with SpringWorks Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| elevate.bio | 100% | 37.6K | #1,544,839 | View details | |
| acadia.com | 89% | 37.8K | #803,210 | View details | |
| revmed.com | 89% | 83.2K | #872,423 | View details | |
emdgroup.com | emdgroup.com | 89% | #257,460 | – | |
bioworld.com | bioworld.com | 89% | #311,180 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for SpringWorks Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as SpringWorks Therapeutics (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Springworks Therapeutics
Complete news archive for SpringWorks Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SpringWorks Therapeutics
SpringWorks Therapeutics was founded in 2017.
SpringWorks Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Saqib Islam is the CEO of SpringWorks Therapeutics, as recorded in our data.
SpringWorks Therapeutics is a funded company, having raised a total of $229.6M across 4 funding rounds to date. The company's 1st funding round was a Series A of $103M, raised on Sep 2017.
Founded in 2017 and based in New York, United States, small molecule therapeutics are developed by SpringWorks Therapeutics within the biotechnology sector for cancer and rare diseases. Operations focus on advancing candidates such as Nirogacestat, a gamma-secretase inhibitor targeting desmoid tumors, a MEK 12 inhibitor for neurofibromatosis type 1, and senicapoc for hereditary xerocytosis involving dehydrated red blood cells.
SpringWorks Therapeutics's top competitors include Vuja De Sciences, QSAM Biosciences and ECM Therapeutics.
SpringWorks Therapeutics offers Nirogacestat and Mirdametinib.
SpringWorks Therapeutics operates through Springworks Therapeutics, Inc..
Yes. SpringWorks Therapeutics was acquired by Merck in April 2025.